Scancell Holdings plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNLF research report →
About the company
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers.
- CEO
- Phillip John L'Huillier
- IPO
- 2013
- Employees
- 61
- HQ
- Oxford, GB
Price Chart
- Market Cap
- $289.44M
- P/E
- -26.89
- P/S
- 31.39
- P/B
- -17.66
- EV/EBITDA
- -27.79
- Div Yield
- 0.00%
- Gross Margin
- 78.45%
- Op Margin
- -283.34%
- Net Margin
- -116.98%
- ROE
- 90.29%
- ROIC
- -113.84%
- Revenue
- $4.71M · -10.62%
- Net Income
- $-12,272,000 · -2.82%
- EPS
- $-0.01 · -85.29%
- Op Income
- $-15,001,000
- FCF YoY
- 59.51%
- 52W High
- $0.33
- 52W Low
- $0.12
- 50D MA
- $0.27
- 200D MA
- $0.18
- Beta
- 0.74
- Avg Volume
- 1.81K
Get TickerSpark's AI analysis on SCNLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SCNLF coverage
Recent articles, reports, and earnings notes.
No research on SCNLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCNLF report →Similar companies
Peers in the same neighborhood.